Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment

Cleveland Clinic Journal of Medicine

Volumn 76, Issue SUPPL.3, 2009, Pages

  Sherman, Morris ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

BLOOD; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; REVIEW; RISK ASSESSMENT; VIROLOGY; VIRUS LOAD;

ALANINE TRANSAMINASE; CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER NEOPLASMS; REVERSE TRANSCRIPTASE INHIBITORS; RISK ASSESSMENT; VIRAL LOAD;

EID: 68049127992     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.76.s3.02     Document Type: Article

References (11)

1. Bruix J, Sherman M. Management of hepatocellular carcinoma. AASLD Practice Guideline. Hepatology 2005; 42:1208-1235.
2. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006; 101:1797-1803.
3. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Chronic hepatitis B virus infection and mortality from nonliver causes: results from the Haimen City cohort study [published online ahead of print January 19, 2005]. Int J Epidemiol 2005; 34:132-137.
4. Chen C-J, Yang H-I, Su J, et al; for the REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73.
5. Yu M-W, Yeh S-H, Chen P-J, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97:265-272.
6. Chen C-J, Yang H-I, Iloeje UH, et al. A risk function nomogram for predicting HCC in patients with chronic hepatitis B: the REVEAL-HBV study [AASLD abstract S1766]. Gastroenterology 2007; 132(suppl 2):A761.
7. Yuen M-F, Yuan H-J, Wong DK-H, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005; 54:1610-1614.
8. Liaw Y-F, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
9. Yuen MF, Seto WK, Chow DHF, et al. Long-term beneficial outcome of Chinese asymptomatic patients with HBeAg-positive chronic hepatitis B on continuous lamivudine therapy: 7-year experience [AASLD abstract 985]. Hepatology 2005; 42(suppl 1):583A.
10. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40:883-891.
11. Hoshida Y, Villaneuva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359:1995-2004.